Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.153
Sell
RSI(14)
31.173
Neutral
STOCH(KDJ)(9,3,3)
39.029
Buy
ATR(14)
0.363
High Vlolatility
CCI(14)
-54.061
Neutral
Williams %R
77.119
Sell
TRIX(12,20)
-3.509
Sell
StochRSI(14)
100.000
Buy
Search
CEL-SCI Corp
CVMAdd to Watchlist
1.430USD
+0.130+10.00%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
12.04MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of CEL-SCI Corp
Currency: USD Updated: 2026-05-15Key Insights
CEL-SCI Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 135 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
CEL-SCI Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
CEL-SCI Corp Highlights
StrengthsRisks
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Overvalued
The company’s latest PE is -0.39, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 783.72K shares, decreasing 30.79% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.41.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
25.000
Target Price
+1823.08%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of CEL-SCI Corp is 5.93, ranking 302 out of 382 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low.
Score
Financials
6.21
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.98
Operational Efficiency
2.66
Growth Potential
6.75
Shareholder Returns
7.03
CEL-SCI Corp's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of CEL-SCI Corp is 7.16, ranking 150 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.39, which is -91.33% below the recent high of -0.03 and -1069.62% above the recent low of -4.52.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 135/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of CEL-SCI Corp is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 300.00, with a high of 300.00 and a low of 300.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
25.000
Target Price
+1823.08%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
CEL-SCI Corp
CVM
1
CRISPR Therapeutics AG
CRSP
27
Beigene Ltd
ONC
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of CEL-SCI Corp is 7.01, ranking 110 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.48 and the support level at 0.13, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.306
Buy
MA10
1.471
Sell
MA20
2.343
Sell
MA50
3.218
Sell
MA100
4.156
Sell
MA200
6.280
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of CEL-SCI Corp is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 9.27%, representing a quarter-over-quarter increase of 11.67%. The largest institutional shareholder is James Simons, holding a total of 35.89K shares, representing 0.42% of shares outstanding, with 1.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of CEL-SCI Corp is 2.09, ranking 242 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.61. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.58
VaR
+9.52%
240-Day Maximum Drawdown
+90.87%
240-Day Volatility
+145.12%
Return
Best Daily Return
60 days
+24.50%
120 days
+24.50%
5 years
+45.09%
Worst Daily Return
60 days
-25.88%
120 days
-25.88%
5 years
-45.46%
Sharpe Ratio
60 days
-3.13
120 days
-1.89
5 years
-0.47
Risk Assessment
Maximum Drawdown
240 days
+90.87%
3 years
+93.79%
5 years
+98.51%
Return-to-Drawdown Ratio
240 days
-0.47
3 years
-0.16
5 years
-0.17
Skewness
240 days
+0.29
3 years
+0.55
5 years
+0.55
Volatility
Realised Volatility
240 days
+145.12%
5 years
+197.94%
Standardised True Range
240 days
+44.49%
5 years
+24.14%
Downside Risk-Adjusted Return
120 days
-257.82%
240 days
-257.82%
Maximum Daily Upside Volatility
60 days
+109.66%
Maximum Daily Downside Volatility
60 days
+126.82%
Liquidity
Average Turnover Rate
60 days
+5.11%
120 days
+3.21%
5 years
--
Turnover Deviation
20 days
-36.14%
60 days
-75.40%
120 days
-84.52%
Peer Comparison
Biotechnology & Medical Research
CEL-SCI Corp
CVM
6.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
